Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2007-06-05
2007-06-05
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S164000, C514S620000
Reexamination Certificate
active
10546131
ABSTRACT:
The invention provides compounds of formulain which m, n, R1, R2, R3, R4, and R5, have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
REFERENCES:
patent: 3464998 (1969-09-01), Krimmel
patent: 3471491 (1969-10-01), Venkatachala et al.
patent: 4349552 (1982-09-01), Takaya et al.
patent: 4751292 (1988-06-01), Fox
patent: 6201024 (2001-03-01), Baxter et al.
patent: 6242470 (2001-06-01), Baxter et al.
patent: 6492355 (2002-12-01), Alcaraz et al.
patent: 6720452 (2004-04-01), Alcaraz et al.
patent: 6949539 (2005-09-01), Alcaraz et al.
patent: 7129246 (2006-10-01), Alcaraz et al.
patent: 2001/0003121 (2001-06-01), Baxter et al.
patent: 2002/0193414 (2002-12-01), Alcaraz et al.
patent: 2003/0013704 (2003-01-01), Alcaraz et al.
patent: 2003/0144293 (2003-07-01), Duplantter et al.
patent: 2004/0236109 (2004-11-01), Van Straten et al.
patent: 2005/0090524 (2005-04-01), Ford et al.
patent: 2006/0247257 (2006-11-01), Dixon
patent: 650919 (1964-07-01), None
patent: 1943404 (1970-12-01), None
patent: 0002065 (1979-05-01), None
patent: 0867436 (1998-09-01), None
patent: 1310493 (2003-05-01), None
patent: WO 95/04720 (1995-02-01), None
patent: WO 99/18074 (1999-04-01), None
patent: WO 99/29660 (1999-06-01), None
patent: WO 99/29661 (1999-06-01), None
patent: WO 00/61569 (2000-10-01), None
patent: WO 01/42194 (2001-06-01), None
patent: WO 01/44170 (2001-06-01), None
patent: WO 02/096426 (2002-12-01), None
patent: WO 03/042191 (2003-05-01), None
patent: WO 03041707 (2003-05-01), None
patent: WO 03/080579 (2003-10-01), None
patent: WO 04/073704 (2004-09-01), None
patent: WO 04/105796 (2004-12-01), None
patent: WO 04/105797 (2004-12-01), None
patent: WO 04/105798 (2004-12-01), None
patent: WO 05/014529 (2005-02-01), None
patent: WO 05/025571 (2005-03-01), None
Accession No. 2003:42109, CAS Registry No. 487064-48-2, 2003.
Alcaraz et al., Preparation of Adamantane Derivatives as P2X7 Receptor Antagonists, CAS Accession No. 2001:904155.
Alcaraz et al., “Novel P2X7 Antagonists”Bioorganic and Medicinal Chemistry Letters, 13:4043-4046 (2003).
Baxter et al., “Hit-to-Lead Studies: The Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists,”Bioorganic and Medical Chemistry Letters, 13:4047-4050 (2003).
Bourrie et al., “SSR125329A, A High Affinity Receptor Ligand with Potent Anti-Inflammatory Properties,”Eur. J. of Pharm.,456:123-131 (2002).
Costakis et al., “Synthesis of Some Adamantane Derivatives of 2-Aminobenzothiazoles”,Journal of Medicinal Chemistry14(12):1222-1223 (1971).
Dell 'Antonio et al., “Antinociceptive effect of a new P2zP2X7 antagonist, oxidized ATP, in arthritic rats”,Neuroscience Letters327:87-90 (2002).
Di Virgilio et al., “Purinergic P2X—Receptor: A Pivotal in Inflammation and Immunomodulation”,Drug Development Research45:207-213 (1998).
Ferrari et al., “Extracellular ATP Triggers IL-1 β Release by Activating the Purinergic P2Z Receptor of Human Macrophages”,J. Immunol.159:1451-1458 (1997).
Ferrari et al., “Purinergic Modulation of Interleukin- 1 β Release from Microglial Cells Stimulated with Barterial Endotoxin”,J. Exp. Med.185(3):579-582 (1997).
Henderson et al., “Inhibition of interleukin-1 -induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist”,Cytokine3(3):246-249 (1991).
Ho et al., “Synthesis of a Peptidomimetic Tricyclic Tetrahydrobenzo[ij] quinoline as a VLA-4 Antagonist”,Org. Chem.65:6743-6748, p. 6745, scheme 5, (27) (2000).
Humphreys et al., “Modulation of P2X7nucleotide receptor expression by pro-and anti-inflammatory stimuli in THP-1 monocytes”,Journal of Leukocyte Biology64:265-273 (1998).
Kadota et al., “Significance of IL-1 β and IL-1 receptor antagonist (IL-1 Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB)”,Clin Exp. Immunol.103:461-466 (1996).
Kburana et al., “Clinical aspects of rheumatoid arthritis”, Pathophysiology, vol. 12, Issue 3, Abstract (2005).
Kirkham, “Interleukin-1, Immune Activation Pathways, and Different Mechanisms in Osteoarthritis and Rheumatoid Arthritis”,Annals of the Rheumatic Diseases, 50:395-400 (1991).
Li et al., “Should atherosclerosis be considered a cancer of the vascular wall?”Medical Hypotheses, 64:694-698 (2005).
Otterness et al., “Possible Role of IL-1 in Arthritis: Effects of Prostaglandins in the Regulation of IL-1 Synthesis and Actions”, Agent Act 39 (Suppl):109-120 (1993).
Mackenzie et al., “Could rheumatoid arthritis have an infectious aetiology?” Drug Discovery Today: Disease Mechanism, vol. 2, Issue 3, Abstract (2005).
Rains et al., “Sulfasalazine, A review of its Pharmacoligical Properties and Therapeutic Efficacy in the Treatment of Rheumatoid Arthritis”,Drugs50:137-156 (1995).
Richards et al., “Substituted 2-Phenyl-benzimidazole Derivatives: Novel Compounds that Suppress Key Markers of Allergy,” Eur. J. of Medic. Chem., 41:950-969 (2006).
Sakito et al., “Interleukin 1 β, Tumor Necrosis Factor Alpha, and Interleukin 8 in Bronchoalveolar Lavage Fluid of Patients with Diffuse Panbronchiolitis: A Potential Mechanism of Macrolide Therapy”,Respiration63:42-48 (1996).
Seventh International Symposium on Adenosine & Adenine Nucleotides: “Adenosin-und Purinrezeptoren als Targets neuer Arneimittel”,Deutsche Apotheker Zeitung142(36):62-65 (2002).
STN International, File REGISTRY, see RN 405068-97-5, 405070-41-9, 405076-22-4, Apr. 14, 2002.
STN International, File REGISTRY, see RN 445032-09-7, Aug. 30, 2002.
STN International, File CHEMCATS, Accession No. 2001:48444, May 14, 2001, NS18552, 2-Quinolinecarboxamide, N-(tricycle[3.3.1.13,7]dec-1-ylmethyl), CAS Registry No. 313688-07-2.
STN International, File REGISTRY, see RN 401622-10-4, Mar. 24, 2002.
van den Berg, Lessons from animals models of osteoarthritis,Curr. Opin. Rheumatol, 13(5): 452-6 (2001)
Yu et al., “Inhibition on IL-1 Release from Human Monocytes and Suppression of Streptococcal Cell Wall and Adjuvant-induced Arthritis in Rats by an Extract ofTripterygium wilfordiiHook”,Gen. Pharmac.25(6):1115-1122 (1994).
Caffrey Moya
Ford Rhonan
Pimm Austen
AstraZeneca AB
Kumar Shailendra
LandOfFree
Adamantane derivatives, processes for their preparation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adamantane derivatives, processes for their preparation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adamantane derivatives, processes for their preparation and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3819199